Expert Financial Analysis and Reporting

Recent Reports

• Kite Pharma: Interpretation of Results from the Interim Look at ZUMA-1 (KITE, Avoid, $60.25) (0)

Recent Blogs

• SmithOnStocks Investment Recommendations Summarized (0)
• Kite Pharma Part 5: Detailed Research That I Have Done In Coming to My Opinion on Kite (KITE, Avoid, $$54.06) (0)
• Bristol-Myers Squibb: Checkmate-026 Trial Fails to Reach Primary Endpoint (BMY, $62.85); A Buying Opportunity (0)
• Antares: Updates on QST and AB Generic to EpiPen; Reiteration of Buy Recommendation (ATRS, Buy, $1.65) (0)
• A Non-Consensus, More Balanced Look at the CAR-T Development Efforts of Kite and Juno (Kite, $48.53: Juno, $30.42) (0)
• Kite Pharma Part 4: A Preview of Highly Anticipated Results from Interim Look at ZUMA-1 (KITE, Avoid, $54.95) (0)
• Relypsa: Company Releases Veltassa Launch Metrics for May (RLYP, $18.14, Buy) (0)
• Kite Pharma Part 3: A Detailed Analysis of the Design of the All-Important ZUMA-1 Trial (0)
• Updates on My Investment Opinion for 15 Stocks I Follow Closely (0)
• Kite Pharma Part 2: An Overview of CAR-T Cell Drug Development Efforts (0)
• Northwest Biotherapeutics (NWBO): Some Thoughts about the Appointment of Two New Board Members (0)

Social Feeds

• • $NWBO Observations of DCVax Direct data discussed in company presentation at ASCO. http://t.co/cIHMg5lfJD, Jun 08
  • $AGEN My takeaways from AGEN's R&D day. KOLs are excited about combining checkpoint modulators with cancer vaccines. http://t.co/a1XJIzXNGF, May 18
  • $nwbo Favorable FDA panel recommendation for Amgen's cancer vaccine is very positive for DCVax vaccines http://t.co/CwIb9CO0eN, May 01
  • $ATRS I believe that 2015 and 2016 could see a breakout for ATRS stock. Here is my sales and profit model http://t.co/xzOr9eEA6c, Apr 23
  • $NWBO Here are my comments on the posters on DCVax Direct and DCVax-L that will be presented at AACR next week, http://t.co/xBtUv9UUJI, Apr 15